We found that a variety of cholecystokinin (CCK) receptor ligands bind to bovine serum albumin (BSA). This binding was rapid, fully reversible, temperature independent, of low affinity, and specific for BSA; it depended on the concentration of BSA, the chemical structure of the ligand, and the chemical composition of the incubation medium.
Peptide hormones are generally considered to exist in a free form in the circulation, and their interaction with receptors is thought to follow the law of mass action. In the course of studying the action of cholecystokinin (CCK), a peptide hormone that affects a variety of gastrointestinal tissues, we found that removing albumin from the incubation solution markedly altered the interaction of CCK with its cell surface receptors and affected its ability to stimulate amylase secretion from pancreatic acini and to cause contraction of gastric smooth muscle cells. Subsequent experiments led us to our working hypothesis that CCK can complex with bovine serum albumin (BSA) and that this complex has biologic activities that differ from those of the free, uncomplexed form of the hormone.
One striking characteristic of albumin is its ability to bind a wide variety of chemically diverse substances (1, 2) . There are domains of albumin that bind small heterocyclic or aromatic carboxylic acids, domains that bind long-chain fatty acids, and domains that bind inorganic metals. Most compounds bind reversibly with low affinities and association constants in the range of 104_106 M-1. In two recent review articles listing the various compounds that have been found to bind to albumin (1, 2) , neither mentions binding of a peptide to albumin.
Receptors for CCK have been divided into two types (CCK-A and CCK-B) based on their pharmacologic properties, amino acid sequences, and tissue distribution (3) (4) (5) (6) (7) . In previous studies using pancreatic acini or COS cells that had been transfected with CCK-A or CCK-B receptors (8- Tissue Preparations. Dispersed acini from rat pancreas were prepared as described (12, 13) . Acini were incubated in a solution containing 24 mM Hepes (pH 7.4), 120 mM NaCl, 7.2 mM KCl, 2.2 mM NaH2PO4,6 mM sodium pyruvate, 6 mM sodium fumarate, 6 mM sodium glutamate, 0.5 mM CaCl2, 1.2 mM MgCl2, 14 mM glucose, 2 mM glutamine, 0.01% (wt/vol) trypsin inhibitor, 1% (vol/vol) essential amino acid mixture, 0.1% (wt/vol) bacitracin, and 1% (vol/vol) vitamin mixture. All incubations were performed with 100% 02 as the gas phase.
Membranes from pancreatic acini were prepared by suspending acini in iced 20 mM Hepes (pH 7.4) containing 0.1% bacitracin, 0.01% trypsin inhibitor, 100 ,uM bestatin, and 3,M phosphoramidon and homogenizing the acini with a Dounce tissue grinder. The homogenate was centrifuged at 200 x g for 5 min. The supernatant was removed and centrifuged at 48,000 x g for 20 min. The pellet containing the membranes was resuspended in acinar membrane solution [10 mM Pipes (pH 6.5), 5 mM MgCl2, 10 mM MnCI2, 0.1% bacitracin, 0.01% trypsin inhibitor, 100 p,M bestatin, and 3 ,uM phosphoramidon].
Dispersed smooth muscle cells from guinea pig stomach were prepared as described (14, 15) and were suspended in incubation solution having the same composition as that used for pancreatic acini except that the concentration of CaCl2 was 1.8 mM.
Amylase Secretion from Pancreatic Acini. Amylase secretion was measured as described (12, 13) . Incubations contained 0.5 ml of acini and were at 37°C for 30 min.
Smooth Muscle Cell Contraction. Contraction was measured as described (14, 15 (16, 17) , also bound to BSA. Binding of the radiolabeled ligands using whole human serum was essentially the same as that observed using the incubation solution containing 1% BSA (Table 1) . Results similar to those given in Table 1 [3H]L-364,718 to BSA is less than that of 1251-CCK-8. Fig. 3 Right illustrates that with pancreatic membranes, BSA was -10 times more potent in inhibiting binding of 125I-CCK-8 than with pancreatic acini (Fig. 3 Left) . This increased potency correlates with the increased binding of 1251-CCK-8 to BSA observed in membrane solution compared to cell solution as illustrated in Fig. 1 .
The results shown in Fig. 4 Left are counterintuitive. Pre- vious results showed that 125I-CCK-8 binds to BSA (Table 1 and Fig. 1 High and low refer to the affinity states of the CCK receptor. The data in Fig. 4 Left were analyzed using the LIGAND program (20 (8) (9) (10) . As illustrated in Fig. 4 Right, BSA did not alter the interaction of L-364,718 with the low-or very-low-affinity states of the CCK-A receptor (Kd of both states = 2 nM). The ability of BSA to cause a 30% decrease in binding of [3HJL-364,718 to pancreatic acini (Fig. 3 ) may result from a decrease in the affinity of the radiolabeled ligand-BSA complex for the pancreatic CCK-A receptor that is too small for us to detect by competitive binding studies. Fig. 4 Right also illustrates that the curve for inhibition of binding of [3H]L-364,718 by CCK-8 is shifted to the right by adding BSA. When these curves were analyzed with the LIGAND program (20) , it appeared that this shift resulted from BSA reducing the affinity of CCK-8 for the Table 2 ) with no change in the affinity of CCK-8 for the very-low-affinity state of the receptor. Fig. 5 Left illustrates that BSA influences the ability of CCK-8 to stimulate amylase secretion from pancreatic acini-an action of CCK-8 mediated by CCK-A receptors (3) . With BSA, CCK-8 caused a 6-fold increase in secretion at 300 pM. Without BSA, the basal rate of secretion was increased, and 300 pM CCK-8 caused a stimulation of secretion that was only 50% of that caused with BSA. This effect of BSA was specific for CCK-8 in that the stimulation of secretion caused by carbachol was not altered. The results in Fig. 5 Left are compatible with the hypothesis that BSA increases the efficacy with which CCK-8 stimulates amylase secretion. The decrease in affinity of CCK-8 for the low-affinity state of the receptor illustrated in Fig. 4 and Table 2 is not sufficient to alter the potency with which CCK-8 stimulates amylase secretion, because occupation of only a small fraction of the low-affinity receptors produces maximal stimulation of secretion (10) .
Fig. 5 Right illustrates that BSA is critical for CCK-8 to cause contraction of dispersed gastric smooth muscle cells-an action of CCK-8 mediated by CCK-B receptors (3, 23) . This dependence on BSA was specific for CCK-8 in that the contraction caused by acetylcholine was not altered by removing BSA from the incubation medium. The possibility that the low activity of CCK-8 without BSA resulted from adsorption of the peptide to the walls of the test tube can be excluded by the findings that under identical incubation conditions, there is no decrease in the concentration of 125I-CCK-8 or [3H]CCK-8 in the medium. These results coupled with our finding that BSA alone did not alter cell length (data not shown) exclude the possibility that BSA is contaminated with significant amounts of bovine CCK.
Previous studies have shown that CCK-8 causes contraction of dispersed gastrointestinal smooth muscle cells in vitro at concentrations that are 100 to 1000 times lower than those that cause contraction of strips of smooth muscle mounted in a chamber (14, 15, (23) (24) (25) (26) . BSA is usually included in the incubation solution used to study dispersed smooth muscle cells in vitro, but it is usually not included in the incubation solution used to study strips of gastrointestinal smooth muscle because BSA causes too much foaming when oxygen is bubbled through the chamber. The results in Fig. 5 show that BSA is a critical determinant of the ability of physiological concentrations of CCK-8 (1-10 pM; ref. 27 ) to cause contraction of gastrointestinal smooth muscle and can account for the difference in sensitivity to CCK-8 between dispersed muscle cells and strips of muscle in vitro (14, 15, (23) (24) (25) (26) . CCK-8 binding to BSA makes it likely, at least for gastrointestinal smooth muscle cells, that the BSA-CCK-8 complex has much greater biologic activity than the free, uncomplexed peptide.
Previously in this paper, we proposed that when CCK-8 is complexed to BSA it has different affinities for the high-and low-affinity states of the pancreatic CCK-A receptor compared to free, uncomplexed CCK-8. An alternate hypothesis is that complexing CCK-8 to BSA does not alter the affinity of CCK-8 for the receptor states but, instead, increases the efficacy of CCK-8 once the complex interacts with the receptor. In pancreatic acini, CCK-8 activates a variety of signal transduction mechanisms (28) and can cause phosphorylation of the CCK receptor (29) . Thus, the decrease in binding of 125I-CCK-8 caused by low concentrations of CCK-8 in the presence of BSA (Fig. 4) could result from a CCK-8-induced biochemical alteration of receptors in the low-affinity state. This alteration could convert them to a very-low-affinity state in which they cannot bind detectable amounts of '25I-CCK-8. We have shown previously (11, 19) 10316 Medical Sciences: Huang et al. (11, 19) ; however, they could also have resulted from the same biochemical alteration as that postulated for CCK-8. Additional support for this hypothesis is the finding that CCK-8 as well as agents that cause loss of high-affinity binding of 125I-CCK-8 to pancreatic acini also causes phosphorylation of the pancreatic CCK-A receptor (29) . Finally, this hypothesis is consistent with the finding that BSA increases the efficacy with which CCK-8 stimulates amylase secretion from pancreatic acini and causes contraction of gastric smooth muscle cells (Fig. 5 ). An important corollary of this hypothesis is that there is actually no high-affinity state of the pancreatic CCK-A receptor. The decrease in binding of 125I-CCK-8 caused by low concentrations of CCK-8, which has been interpreted to reflect the high-affinity state, actually results from a CCK-8-induced biochemical alteration of CCK receptors that abolishes their ability to bind measurable amounts of 125I-CCK-8.
